- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07946757
Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B
A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)
This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Minghui Li, Ph.D
- Numéro de téléphone: 010-84322284
- E-mail: Wuhm2000@sina.com
Lieux d'étude
-
-
-
Beijing, Chine
- Beijing Ditan Hospital, Capital Medical University
-
Contact:
- Minghui Li
-
Xi'an, Chine
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- Shuangsuo Dang
-
Xiamen, Chine
- The First Affiliated Hospital of Xiamen University
-
Contact:
- Xiulan Xue
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Voluntarily participate in this trial and sign the informed consent form;
- Aged 18 to 65 years (inclusive), male or female;
- Body mass index (BMI) between 18 and 32 kg/m² (inclusive);
- HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening;
- No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening;
- HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements;
- Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation.
Exclusion Criteria:
- Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery;
- Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection;
- History of other liver diseases;
- History of liver cirrhosis;
- Imaging suggestive of a suspected malignant hepatic lesion;
- Past or current evidence of hepatic decompensation;
- History of extrahepatic diseases potentially associated with HBV immune status;
- Other diseases associated with vasculitis;
- Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening;
- History of malignancy;
- Prior solid organ or bone marrow transplantation;
- Presence or history of severe psychiatric disorders;
- Severe retinopathy or other serious ophthalmic diseases;
- Prior or current use of prohibited medications;
- Concomitant hematological diseases;
- Abnormal laboratory findings;
- Abnormal QTcF interval;
- History of allergy;
- Lactating female subjects or those with a positive serum pregnancy test at screening;
- Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial;
- Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Groupe 2
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Expérimental: Groupe 1
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Expérimental: Groupe 3
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Expérimental: Groupe 4
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)
Délai: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
HBsAg, HBsAb and HBV DNA levels and changes from baseline
Délai: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroclearance rate
Délai: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroconversion rate
Délai: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Minghui Li, Ph.D, Beijing Ditan Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- ACT201-4-1-002
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .